News
Hosted on MSN12mon
GSK Stock Before Q2 Earnings: To Buy or Not to Buy? - MSNPrice Performance & Valuation Year to date, GSK’s stock has gained 4.8% compared to the industry’s 20.0% growth. The stock has also underperformed the sector and the S&P 500.
GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022.
Hosted on MSN27d
GSK (GSK) is a Top-Ranked Value Stock: Should You Buy?For new and old investors, taking full advantage of the stock market and investing with confidence are common ... which is more than double the S&P 500's performance over the same time frame. However, ...
GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK (NYSE:GSK), the $73bn market cap (at the time of writing), United Kingdom based Pharma giant announced its Q223 and H123 results today. The company's share price performance has been flat for ...
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other best undervalued UK stocks to buy right now. The UK and Europe’s Performance in Q1 2025 ...
GSK (GSK) closed at $37.56 in the latest trading session, marking a +0.59% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.43%. On the other hand ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results